High Quality Stocks
RX.CA is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
BIOSYENT INC (RX.CA) Stock Price & Overview
TSX-V:RX • CA0906901081
Current stock price
14.87 CAD
+0.07 (+0.47%)
Last:
The current stock price of RX.CA is 14.87 CAD. Today RX.CA is up by 0.47%. In the past month the price decreased by -4.06%. In the past year, price increased by 50.2%.
RX.CA Key Statistics
52-Week Range9.2 - 15.8
Current RX.CA stock price positioned within its 52-week range.
1-Month Range13.81 - 15.7
Current RX.CA stock price positioned within its 1-month range.
- Market Cap
- 170.708M
- P/E
- 23.98
- Fwd P/E
- 16.76
- EPS (TTM)
- 0.62
- Dividend Yield
- 1.39%
RX.CA Stock Performance
Today
+0.47%
1 Week
+0.47%
1 Month
-4.06%
3 Months
+16.54%
Longer-term
6 Months +24.12%
1 Year +50.20%
2 Years +72.91%
3 Years +95.66%
5 Years +90.64%
10 Years +114.27%
RX.CA Stock Chart
RX.CA Stock Screens
RX.CA currently appears in the following ChartMill screener lists.
RX.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RX.CA. When comparing the yearly performance of all stocks, RX.CA is one of the better performing stocks in the market, outperforming 73.84% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. Both the health and profitability get an excellent rating, making RX.CA a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RX.CA Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 19, 2026
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
RX.CA Forecast & Estimates
7 analysts have analysed RX.CA and the average price target is 16.83 CAD. This implies a price increase of 13.18% is expected in the next year compared to the current price of 14.87.
For the next year, analysts expect an EPS growth of 20.96% and a revenue growth 23.16% for RX.CA
Analysts
Analysts82.86
Price Target16.83 (13.18%)
EPS Next Y20.96%
Revenue Next Year23.16%
RX.CA Groups
Sector & Classification
RX.CA Financial Highlights
Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 24.84% compared to the year before.
Income Statements
Revenue(TTM)42.18M
Net Income(TTM)8.63M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.47% | ||
| ROA | 18.07% | ||
| ROE | 21.64% | ||
| Debt/Equity | 0.02 |
Chartmill High Growth Momentum
EPS Q2Q%19.41%
Sales Q2Q%27.9%
EPS 1Y (TTM)24.84%
Revenue 1Y (TTM)22.22%
RX.CA Ownership
Ownership
Inst Owners3.76%
Shares11.48M
Float7.84M
Ins Owners17.83%
Short Float %N/A
Short RatioN/A
RX.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.23 | 2.772B | ||
| CRON | CRONOS GROUP INC | 39.18 | 1.338B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.066B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.17 | 904.914M | ||
| GUD | KNIGHT THERAPEUTICS INC | 155.29 | 730.324M | ||
| DHT-U | DRI HEALTHCARE TRUST | 3.83 | 671.122M | ||
| WEED | CANOPY GROWTH CORP | N/A | 565.768M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 22.49 | 475.264M | ||
| TSND | TERRASCEND CORP | N/A | 349.699M | ||
| HITI | HIGH TIDE INC | 10.35 | 283.038M | ||
| ACB | AURORA CANNABIS INC | 59.28 | 271.641M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.16 | 261.773M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 221.245M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About RX.CA
Company Profile
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Company Info
IPO: 1981-05-22
BIOSYENT INC
2476 Argentia Road, Suite 402
Mississauga ONTARIO L5N 6M1 CA
CEO: Rene Goehrum
Employees: 0
Phone: 18884390013
BIOSYENT INC / RX.CA FAQ
What does RX do?
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Can you provide the latest stock price for BIOSYENT INC?
The current stock price of RX.CA is 14.87 CAD. The price increased by 0.47% in the last trading session.
Does BIOSYENT INC pay dividends?
BIOSYENT INC (RX.CA) has a dividend yield of 1.39%. The yearly dividend amount is currently 0.18.
How is the ChartMill rating for BIOSYENT INC?
RX.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What do analysts say about BIOSYENT INC (RX.CA) stock?
7 analysts have analysed RX.CA and the average price target is 16.83 CAD. This implies a price increase of 13.18% is expected in the next year compared to the current price of 14.87.
Is BIOSYENT INC (RX.CA) expected to grow?
The Revenue of BIOSYENT INC (RX.CA) is expected to grow by 23.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of RX stock?
BIOSYENT INC (RX.CA) has a market capitalization of 170.71M CAD. This makes RX.CA a Micro Cap stock.